Skip to main content
Fig. 6 | Journal for ImmunoTherapy of Cancer

Fig. 6

From: Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment

Fig. 6

NKG2A-HLA-E pathway is engaged during the cocultures and NKG2A blockade synergizes with anti-MICA/B antibodies. a NKG2A expression by CD4 T cells, CD8 T cells and NK cells in the IN and OUT compartments and in the presence or not of IL-15, analyzed by flow cytometry at 24 h. n = 17 independent experiments. b HLA-E expression by tumor cells in the spheroids cocultured or not with CD19-CD14- PBMCs, analyzed by flow cytometry (n = 16 independent experiments) and immunohistochemistry (representative pictures of 1 experiment) at 24 h. c to e Analyses of (c, n = 4) caspase-3/− 7 activity, (d, n = 10) spheroid volume, and (e, n = 10) spheroid infiltration 48 h after coculturing HT29 spheroids with CD19-CD14- PBMCs in the presence or not of anti-NKG2A blocking antibodies or corresponding control isotype. f to h Analyses of (f, n = 7) spheroid volume, (g, n = 7) tumor cell apoptosis, and (h, n = 7) spheroid infiltration 48 h after coculturing HT29 spheroids with CD19-CD14- PBMCs in the presence or not of anti-MICA/B antibodies alone or combined with anti-NKG2A blocking antibodies, or with corresponding control isotype antibodies alone or combined. Statistical significance of c panel was analyzed using 2-way ANOVA, the other panels using the Wilcoxon matched-pairs signed rank test (* p < 0.05; ** p < 0.005, *** p < 0.001, **** p < 0.0001)

Back to article page